Defibrotide for the Treatment of Severe COVID-19

Recruiting now · Phase 2

Conditions studied: Covid19

In brief

The goal of this study is to evaluate the safety and feasibility of defibrotide in COVID-19 pneumonia.

Key facts

Study ID

NCT04652115

Run by

Brigham and Women's Hospital

People needed

42

Starts

2021-01-01

Expected to finish

2027-01-01

Last updated by the study team

2026-07-20

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age ≥18 years.
• Active COVID-19 infection confirmed by positive SARS-CoV-2 PCR.
• Radiographic evidence of bilateral pulmonary infiltrates.
• A life expectancy of at least 24 hours.
• Score of 4-7 on the WHO ordinal scale.
• Prophylactic dose anticoagulation is allowed for enrollment into cohort 1. Therapeutic dose anticoagulation for active thrombosis, ECMO, and/or continuous renal replacement therapy (CRRT) is allowed for enrollment into cohort 2 if there is no evidence of bleeding after at least 24 hours of anticoagulation.
• Patient or surrogate able to provide informed consent

You may not qualify if…

• Clinically significant acute bleeding.
• Concomitant use of thrombolytic therapy (e.g. t-PA).
• Hemodynamic instability, defined as a requirement for >1 vasopressor agent for enrollment into cohort 1, and a requirement for >2 vasopressor agents for enrollment into cohort 2
• Known allergy or hypersensitivity to DF.
• Pregnant or lactating.

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.